About Carboxypeptidase B
Carboxypeptidase B (CPB1) is a protein
from Homo sapiens identified by UniProt accession
P15086, 417 residues long.
MolForge cross-references it against 0 known binders and
176 disease associations.
Target properties
| Protein name | Carboxypeptidase B |
| UniProt accession | P15086 |
| Gene | CPB1 |
| Organism | Homo sapiens |
| Length | 417 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (176)
Diseases linked to this target (Open Targets).
- neuroinflammatory disorder · score 0.30
- blood protein measurement · score 0.29
- protein measurement · score 0.29
- mean corpuscular hemoglobin concentration · score 0.21
- endometrial cancer · score 0.18
- pancreatic adenocarcinoma · score 0.16
- cutaneous melanoma · score 0.13
- squamous cell lung carcinoma · score 0.10
- head and neck squamous cell carcinoma · score 0.10
- adolescent idiopathic scoliosis · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P15086-F1 | alphafold | PREDICTED | 95.34 | — |
Amino-acid sequence (417 residues)
MLALLVLVTV ALASAHHGGE HFEGEKVFRV NVEDENHINI IRELASTTQI DFWKPDSVTQ IKPHSTVDFR VKAEDTVTVE NVLKQNELQY KVLISNLRNV VEAQFDSRVR ATGHSYEKYN KWETIEAWTQ QVATENPALI SRSVIGTTFE GRAIYLLKVG KAGQNKPAIF MDCGFHAREW ISPAFCQWFV REAVRTYGRE IQVTELLDKL DFYVLPVLNI DGYIYTWTKS RFWRKTRSTH TGSSCIGTDP NRNFDAGWCE IGASRNPCDE TYCGPAAESE KETKALADFI RNKLSSIKAY LTIHSYSQMM IYPYSYAYKL GENNAELNAL AKATVKELAS LHGTKYTYGP GATTIYPAAG GSDDWAYDQG IRYSFTFELR DTGRYGFLLP ESQIRATCEE TFLAIKYVAS YVLEHLY
Explore Carboxypeptidase B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets